Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization

[1]  K. Bruxvoort,et al.  Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 , 2023, Nature Communications.

[2]  A. Gordon,et al.  Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants , 2022, Cell.

[3]  P. Austin,et al.  Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes , 2022, Nature Communications.

[4]  J. Lewnard,et al.  Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome , 2022, Nature Communications.

[5]  Inga Nehlmeier,et al.  Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation , 2022, The Lancet Infectious Diseases.

[6]  W. Dowling,et al.  Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant , 2022, npj Vaccines.

[7]  J. L. Bernal,et al.  Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England , 2022, The Lancet Regional Health - Europe.

[8]  M. Exline,et al.  Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022. , 2022, MMWR. Morbidity and mortality weekly report.

[9]  William F. Fadel,et al.  Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods , 2022, medRxiv.

[10]  J. McLaughlin,et al.  Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study , 2022, The Lancet Respiratory Medicine.

[11]  O. A. Ogun,et al.  BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5 , 2022, The Lancet Infectious Diseases.

[12]  N. Bar-Zeev,et al.  Post-Vaccination Neutralization Responses to Omicron Sub-Variants , 2022, medRxiv.

[13]  L. Bekker,et al.  Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa , 2022, The New England journal of medicine.

[14]  P. Austin,et al.  Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes , 2022, JAMA network open.

[15]  William F. Fadel,et al.  Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[16]  Rupal M Mody,et al.  Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection , 2022, bioRxiv.

[17]  O. Pybus,et al.  Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa , 2022, Nature Medicine.

[18]  D. Khoury,et al.  Neutralising antibodies predict protection from severe COVID-19 , 2022, medRxiv.

[19]  Minal K. Patel,et al.  Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant , 2022, The Lancet Infectious Diseases.

[20]  O. Wichmann,et al.  Facing the Omicron variant—how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review , 2022, Frontiers in Immunology.

[21]  K. To,et al.  Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong , 2022, bioRxiv.

[22]  L. Abu-Raddad,et al.  Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization , 2022, Vaccine.

[23]  J. L. Bernal,et al.  Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study , 2022, Nature Communications.

[24]  J. L. Bernal,et al.  COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England , 2022, The Lancet Infectious Diseases.

[25]  Gheyath K Nasrallah,et al.  Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.

[26]  S. Zeger,et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.

[27]  Jian K. Liu,et al.  Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma , 2022, Emerging microbes & infections.

[28]  U. Rand,et al.  Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations , 2021, Scientific Reports.

[29]  Bibiana I Ferreira,et al.  Comparative COVID-19 Vaccines Effectiveness in Preventing Infections, Hospitalizations, and Deaths with SARS-CoV-2 BA.5 and Ba.2 Omicron Lineages: A Case-Case and Cohort Study Using Electronic Health Records in Portugal , 2022, SSRN Electronic Journal.

[30]  L. Bekker,et al.  Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa , 2021, The New England journal of medicine.

[31]  Qiang Liu,et al.  Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost , 2021, Emerging microbes & infections.

[32]  K. Mølbak,et al.  Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study , 2021, medRxiv.

[33]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[34]  M. Lipsitch,et al.  Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results , 2019, Epidemiology and Infection.

[35]  John Adams.  Assessing , 2020, Transport Planning.